Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (103)	7/12/2002 2:48:32 AM
From: RWReeves	Respond to of 684

An interesting thing about the VPHM viral meningitis trial results was that the mild cases did not improve over control but the more severe cases did, to the point of reduced mortality if memory serves. But that wasn't the endpoint, so yes, it did not make the grade from a prospective PIII requirement. That has continued to intrigue me and I have oft wondered why they did not restructure the trial and go for that endpoint instead. Dare we consider what the untraveled road of off label might look like as opposed to the Bupkis they've now ended up with? Sigh. RWR